112 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
15
Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.
Integral Biosciences
27
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.
Pfizer
2
Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays.
College of Chemical and Environmental Engineering
51
The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.
Epizyme
26
Discovery, design, and synthesis of indole-based EZH2 inhibitors.
Constellation Pharmaceuticals
34
Selective inhibitors of protein methyltransferases.
Icahn School Of Medicine At Mount Sinai
4
The role of enhancer of zeste homologue 2 inhibitors in controlling epigenetics and their potential for cancer treatment.
Therachem Research Medilab (India)
47
Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2.
Constellation Pharmaceuticals
6
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
TBA
25
Discovery of Highly Potent and Selective EZH2 Covalent Inhibitors via Incorporating Basic Amines.
Sun Yat-Sen University
9
Next-generation cancer therapeutics: PROTACs and the role of heterocyclic warheads in targeting resistance.
Acharya & BM Reddy College of Pharmacy
23
Current and Emerging Approaches Targeting G9a for the Treatment of Various Diseases.
Sichuan University
32
One stone two birds: Introducing piperazine into a series of nucleoside derivatives as potent and selective PRMT5 inhibitors.
Ocean University of China
1
Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma.
National University of Singapore
3
Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma.
University of Nottingham
2
PRC2 Is Dispensable in Vivo for β-Catenin-Mediated Repression of Chondrogenesis in the Mouse Embryonic Cranial Mesenchyme.
Case Western Reserve University
1
Signaling function of PRC2 is essential for TCR-driven T cell responses.
The Rockefeller University
11
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
UNC Eshelman School of Pharmacy
10
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
Epizyme, Inc.
2
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Daiichi Sankyo Co., Ltd
14
Design, synthesis and activity evaluation of quinolinone derivatives as EZH2 inhibitors.
Southeast University
34
Discovery of dihydropyridinone derivative as a covalent EZH2 degrader.
Chinese Academy of Sciences
14
Synthesis and application of small molecules approved for the treatment of lymphoma.
The First Affiliated Hospital of Zhengzhou University
40
Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2.
Sun Yat-Sen University
29
Design, Synthesis, and Biological Evaluation of Potent EZH2/LSD1 Dual Inhibitors for Prostate Cancer.
Sun Yat-sen University Cancer Center
19
Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).
Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
31
Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors.
Sun Yat-Sen University
43
Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas.
Shenyang Pharmaceutical University
36
Structure-based discovery of a new series of nucleoside-derived ring-opening PRMT5 inhibitors.
University of Chinese Academy of Sciences
38
Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.
Zhengzhou University
36
Pyrrole-containing hybrids as potential anticancer agents: An insight into current developments and structure-activity relationships.
Jiangxi Science & Technology Normal University
16
Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.
China Pharmaceutical University
9
Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies.
First Affiliated Hospital of Gannan Medical University
19
Fused Tetrahydroquinolines Are Interfering with Your Assay.
University of North Carolina at Chapel Hill
12
First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity
Taipei Medical University
19
Recent advances in EZH2-based dual inhibitors in the treatment of cancers.
Xinxiang University
27
Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP.
Sun Yat-Sen University
17
Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2.
Sun Yat-Sen University
5
Discovery of Dual Lysine Methyltransferase G9a and EZH2 Inhibitors with In Vivo Efficacy against Malignant Rhabdoid Tumor.
Shenyang Pharmaceutical University
16
Discovery of cysteine-targeting covalent histone methyltransferase inhibitors.
Nanjing Medical University
34
A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives.
China Pharmaceutical University
2
Small-Molecule Hydrophobic Tagging: A Promising Strategy of Druglike Technology for Targeted Protein Degradation.
China Pharmaceutical University
13
Design, synthesis and mechanism studies of dual EZH2/BRD4 inhibitors for cancer therapy.
China Pharmaceutical University
24
Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors.
Sichuan University
9
Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer.
Sichuan University
47
Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones as Potent NSD2 Inhibitors.
Shanghai Jiao Tong University
20
Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets.
University of Palermo
10
Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation.
Second Military Medical University (Naval Medical University)
2
Focused Libraries for Epigenetic Drug Discovery: The Importance of Isosteres.
University of Pennsylvania
14
Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).
Sapienza University of Rome
2
Targeting Autophagy-Related Epigenetic Regulators for Cancer Drug Discovery.
West China Hospital of Sichuan University
68
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Menoufia University
38
Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5.
Sun Yat-Sen University
13
Design and Synthesis of Dual EZH2/BRD4 Inhibitors to Target Solid Tumors.
Sun Yat-Sen University Cancer Center
61
Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues.
Csir-Indian Institute of Chemical Biology
6
Novel Quinoline Compounds as EZH2 Inhibitors for Treating Cancer.
Smith, Gambrell & Russell
34
Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Sanquan College of Xinxiang Medical University
105
Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.
Affiliated Hospital of Guangdong Medical University
36
Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
Sapienza University of Rome
83
Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Indian Institute of Technology (B.H.U.)
31
Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
China Pharmaceutical University
19
Targeting EZH2 for cancer therapy: From current progress to novel strategies.
West China Hospital
24
A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors.
Tri-Institutional Therapeutics Discovery Institute
22
Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2.
Sichuan University
28
Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
Chinese Academy of Sciences
8
Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA.
China Pharmaceutical University
27
Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
China Pharmaceutical University
44
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Chinese Academy of Sciences
13
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymp
Constellation Pharmaceuticals
2
Design and Characterization of a Pyridone-Containing EZH2 Inhibitor Phosphate Prodrug.
TBA
29
Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
Northwestern University
26
Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.
University of Michigan Medical School
28
Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors.
Sichuan University and Collaborative Innovation Center
26
Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time.
Constellation Pharmaceuticals
6
Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
Sapienza University of Rome
15
New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms.
University College London
54
Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
Icahn School Of Medicine At Mount Sinai
7
Histone methyl transferases: A class of epigenetic opportunities to counter uncontrolled cell proliferation.
Punjabi University
25
Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma.
Shanghai Hengrui Pharmaceutical
33
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquin
Wuxi Apptec
57
Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2
Enliven Therapeutics
21
Compounds and methods useful for treating or preventing cancers
The Broad Institute
17
Compounds as neuronal histamine receptor-3 antagonists and uses thereof
Xw Laboratories
3
Carbonic anhydrases inhibitory effects of new benzenesulfonamides synthesized by using superacid chemistry.
Laboratoire Synthese Et Reactivite Des Substances Naturelles
2
Oxysterol-binding protein (OSBP)-related protein 4 (ORP4) is essential for cell proliferation and survival.
Dalhousie University
15
Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket.
Glaxosmithkline
14
Discovery of Allosteric and Selective Inhibitors of Inorganic Pyrophosphatase from Mycobacterium tuberculosis.
University of Kentucky
459
Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors
Nissan Chemical Industries
5
Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.
Csir-Central Drug Research Institute
2
Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.
Institute of Experimental Botany Ascr and Palacky University
6
Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.
Temple University
2
Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
Banyu Pharmaceutical